Clinical Trial Update: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the addition of mitomycin to BCG as adjuvant intravesical therapy for high-risk non-muscle-invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• Mitomycin (Mitomycin)

Snippet

Sponsor: University of Sydney | Conditions: Bladder Cancer | Phase 3 | Status: UNKNOWN